These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18776936)

  • 61. Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model.
    Olsen AW; Andersen P; Follmann F
    Vaccine; 2014 Feb; 32(6):685-92. PubMed ID: 24365515
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.
    Perrie Y; Kastner E; Kaur R; Wilkinson A; Ingham AJ
    Hum Vaccin Immunother; 2013 Jun; 9(6):1374-81. PubMed ID: 23584249
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
    Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
    Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.
    Dascher CC; Hiromatsu K; Xiong X; Morehouse C; Watts G; Liu G; McMurray DN; LeClair KP; Porcelli SA; Brenner MB
    Int Immunol; 2003 Aug; 15(8):915-25. PubMed ID: 12882829
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
    Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
    J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity.
    McCluskie MJ; Deschatelets L; Krishnan L
    Hum Vaccin Immunother; 2017 Dec; 13(12):2772-2779. PubMed ID: 28537465
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines.
    Qiao C; Liu J; Yang J; Li Y; Weng J; Shao Y; Zhang X
    Biomaterials; 2016 Apr; 85():1-17. PubMed ID: 26851653
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models.
    Ingvarsson PT; Rasmussen IS; Viaene M; Irlik PJ; Nielsen HM; Foged C
    Eur J Pharm Biopharm; 2014 Aug; 87(3):480-8. PubMed ID: 24726978
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adjuvants Based on Synthetic Mycobacterial Cord Factor Analogues: Biophysical Properties of Neat Glycolipids and Nanoself-Assemblies with DDA.
    Kallerup RS; Franzyk H; Schiøth ML; Justesen S; Martin-Bertelsen B; Rose F; Madsen CM; Christensen D; Korsholm KS; Yaghmur A; Foged C
    Mol Pharm; 2017 Jul; 14(7):2294-2306. PubMed ID: 28497975
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
    Abraham S; Juel HB; Bang P; Cheeseman HM; Dohn RB; Cole T; Kristiansen MP; Korsholm KS; Lewis D; Olsen AW; McFarlane LR; Day S; Knudsen S; Moen K; Ruhwald M; Kromann I; Andersen P; Shattock RJ; Follmann F
    Lancet Infect Dis; 2019 Oct; 19(10):1091-1100. PubMed ID: 31416692
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapeutic Vaccination with Cationic Liposomes Formulated with Dioctadecyldimethylammonium and Trehalose Dibehenate (CAF01) and Peptide P10 Is Protective in Mice Infected with
    Araújo MV; Santos Júnior SRD; Nosanchuk JD; Taborda CP
    J Fungi (Basel); 2020 Dec; 6(4):. PubMed ID: 33302372
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice.
    Vangala A; Kirby D; Rosenkrands I; Agger EM; Andersen P; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):787-99. PubMed ID: 16734980
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.
    Nordly P; Agger EM; Andersen P; Nielsen HM; Foged C
    Pharm Res; 2011 Mar; 28(3):553-62. PubMed ID: 21042837
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics.
    Hamborg M; Jorgensen L; Bojsen AR; Christensen D; Foged C
    Pharm Res; 2013 Jan; 30(1):140-55. PubMed ID: 22956169
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies.
    Roces CB; Khadke S; Christensen D; Perrie Y
    Mol Pharm; 2019 Oct; 16(10):4372-4386. PubMed ID: 31437396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.